ArticleBMC health services research2025

Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience.

Neda Yaghoubi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.